271 related articles for article (PubMed ID: 33862558)
1. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
2. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
3. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Hsu HW; de Necochea-Campion R; Williams V; Duerksen-Hughes PJ; Simental AA; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jul; 50(7):662-9. PubMed ID: 24735547
[TBL] [Abstract][Full Text] [Related]
4. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
[TBL] [Abstract][Full Text] [Related]
5. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
6. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Moutafi M; Koliou GA; Papaxoinis G; Economopoulou P; Kotsantis I; Gkotzamanidou M; Anastasiou M; Pectasides D; Kyrodimos E; Delides A; Giotakis E; Papadimitriou NG; Panayiotides IG; Perisanidis C; Fernandez AI; Xirou V; Poulios C; Gagari E; Yaghoobi V; Gavrielatou N; Shafi S; Aung TN; Kougioumtzopoulou A; Kouloulias V; Palialexis K; Gkolfinopoulos S; Strati A; Lianidou E; Fountzilas G; Rimm DL; Foukas PG; Psyrri A
Cancer Res Commun; 2023 Aug; 3(8):1514-1523. PubMed ID: 37575280
[TBL] [Abstract][Full Text] [Related]
7. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
8. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
9. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract][Full Text] [Related]
10. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
11. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Nowsheen S; Bonner JA; Lobuglio AF; Trummell H; Whitley AC; Dobelbower MC; Yang ES
PLoS One; 2011; 6(8):e24148. PubMed ID: 21912620
[TBL] [Abstract][Full Text] [Related]
13. Base excision repair defects invoke hypersensitivity to PARP inhibition.
Horton JK; Stefanick DF; Prasad R; Gassman NR; Kedar PS; Wilson SH
Mol Cancer Res; 2014 Aug; 12(8):1128-39. PubMed ID: 24770870
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
[TBL] [Abstract][Full Text] [Related]
15. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Javle M; Curtin NJ
Ther Adv Med Oncol; 2011 Nov; 3(6):257-67. PubMed ID: 22084640
[TBL] [Abstract][Full Text] [Related]
16. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Nowsheen S; Bonner JA; Yang ES
Radiother Oncol; 2011 Jun; 99(3):331-8. PubMed ID: 21719137
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
[TBL] [Abstract][Full Text] [Related]
19. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F; Italiano A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
